Results 21 to 30 of about 60,444 (298)
Prognostic significance of therapy-induced myelosuppression in newly diagnosed glioblastoma.
Neuro-Oncology, 2022 BACKGROUND Myelosuppression is the major toxicity encountered during temozolomide chemoradiotherapy for newly diagnosed glioblastoma. METHODS We assessed the association of myelosuppression (neutropenia, thrombocytopenia, anemia, lymphopenia) during ...
É. Le Rhun +9 more
semanticscholar +1 more source
Cancer Medicine, 2021 Supportive care interventions used to manage chemotherapy‐induced myelosuppression (CIM), including granulocyte colony‐stimulating factors (G‐CSFs), erythropoiesis‐stimulating agents (ESAs), and red blood cell (RBC) transfusions, are burdensome to ...
R. Ferrarotto +13 more
semanticscholar +1 more source
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2025 Update. [PDF]
Clin Pharmacol TherThiopurine methyltransferase (TPMT) and Nudix hydrolase 15 (NUDT15) are key enzymes that catabolize thiopurines. Decreased or no‐function alleles in TPMT and NUDT15 are associated with reduced or no enzyme activity and predictive of pronounced adverse effects, including severe myelosuppression, that may occur among individuals treated with standard ...
Maillard M +18 more
europepmc +2 more sources
Nutrients, 2022 Myelosuppression is a common and intractable side effect of cancer therapies including radiotherapy and chemotherapy, while the underlying mechanism remains incompletely understood.
Yiding Wu +13 more
semanticscholar +1 more source
Advances in Therapy, 2020 Introduction Chemotherapy-induced myelosuppression (CIM) is one of the most common dose-limiting complications of cancer treatment, and is associated with a range of debilitating symptoms that can significantly impact patients’ quality of life.
R. Epstein +8 more
semanticscholar +1 more source
Patient Preference and Adherence, 2021 Purpose To evaluate which side effects of chemotherapy are considered most burdensome by patients with cancer, identify which health care professionals pay most attention to symptoms associated with chemotherapy-induced myelosuppression (CIM) from the ...
R. Epstein +9 more
semanticscholar +1 more source
Janus kinase 2 inhibition by pacritinib as potential therapeutic target for liver fibrosis
Hepatology, EarlyView., 2022 Diagram of the activation of the profibrotic and procontractile Janus kinase 2 (JAK2)/Ras homolog family member A/Rho‐kinase pathway and the inhibition of phosphorylated JAK2 by pacritinib to inhibit hepatic stellate cell activity. Abstract Background and Aims Janus kinase 2 (JAK2) signaling is increased in human and experimental liver fibrosis with ...
Sandra Torres +21 more
wiley +1 more source
Journal of Medical Economics, 2021 Aims Chemotherapy-induced myelosuppression, which commonly exhibits as neutropenia, anemia, or thrombocytopenia, represents a substantial burden for patients with cancer that affects health-related quality of life and increases healthcare resource ...
R. Epstein +5 more
semanticscholar +1 more source
Severe and prolonged myelosuppression during concomitant temozolomide and radiotherapy treatment in a patient with glioblastoma multiforme [PDF]
, 2015 Aims: We describe the case of a patient with glioblastoma (GBM) who developed severe and prolonged myelosuppression during concomitant daily temozolomide (TMZ) and radiotherapy (RT) treatment.
ALOE SPIRITI, Maria Antonietta +12 more
core +1 more source
Human Cytomegalovirus Infection Suppresses CD34+ Progenitor Cell Engraftment in Humanized Mice
Microorganisms, 2020 Human cytomegalovirus (HCMV) infection is a serious complication in hematopoietic stem cell transplant (HSCT) recipients due to virus-induced myelosuppression and impairment of stem cell engraftment.
Lindsey B. Crawford +6 more
doaj +1 more source